Neuberger Berman Group’s Xenon Pharmaceuticals XENE Stock Holding History

Neuberger Berman Group’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.5M	Buy	206,604 +76,166	+58%	+$4.23M	0.01%	832
2026 Q1	$7.58M	Sell	130,438 -48,309	-27%	-$2.23M	0.01%	887
2025 Q4	$8.01M	Buy	178,747 +6,393	+4%	+$268K	0.01%	858
2025 Q3	$6.92M	Buy	172,354 +24,943	+17%	+$879K	0.01%	888
2025 Q2	$4.61M	Buy	147,411 +102,559	+229%	+$3.35M	﹤0.01%	981
2025 Q1	$1.5M	Sell	44,852 -48,109	-52%	-$1.83M	﹤0.01%	1206
2024 Q4	$3.64M	Buy	+92,961	New	+$3.84M	﹤0.01%	1008

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Neuberger Berman Group's XENE Position: Q2 2026 in Review

Neuberger Berman Group increased its Xenon Pharmaceuticals (XENE) stake by 58% in Q2 2026, buying an estimated $4.23M and bringing the position to 206,604 shares worth $12.5M. The position accounts for 0.01% of the portfolio, ranked #832.

Neuberger Berman Group first reported a position in XENE in Q4 2024 and has held it in 7 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Neuberger Berman Group held 206,604 shares of Xenon Pharmaceuticals worth $12.5M as of Q2 2026.
Neuberger Berman Group bought 76,166 Xenon Pharmaceuticals shares in Q2 2026, an estimated $4.23M.
Xenon Pharmaceuticals made up 0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #832 holding.
Neuberger Berman Group first reported a position in Xenon Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.